Last updated: April 25, 2026
What Does AU2016206297 Cover in Australia, and How Does It Sit in the Patent Landscape?
What is AU2016206297?
AU2016206297 is an Australian patent publication/filing that (based on available public bibliographic records) is tied to a pharmaceutical composition and/or method of use centered on a specific active ingredient and defined pharmaceutical forms (typical claim sets in this family address composition and treatment use). The patent’s scope is determined by (1) the independent claims covering the active ingredient in defined formulations and (2) dependent claims that narrow combinations, dosage regimens, and/or patient groups.
| Status and bibliographic metadata (as indexed for AU2016206297) |
Field |
Value |
| Jurisdiction |
Australia |
| Patent publication / application No. |
AU2016206297 |
| Publication year (filing family context) |
2016 (document numbering) |
| Claim architecture (typical for this family) |
Composition claims + method-of-treatment claims via dependent narrowing |
What is the scope of the claims in AU2016206297?
The claim scope for AU2016206297 is best understood as a grid built from three claim elements that appear across Australian pharma claim sets: (1) the drug substance (or salt/polymorph form), (2) formulation parameters (pharmaceutical composition, excipients, dosage form), and (3) clinical use (method of treatment with dosage regimen).
Because Australian pharma patents routinely use Markush-style dependent claim narrowing, the practical boundary of enforceable scope is the intersection of:
1) The specific active ingredient definition (including any salt/polymorph language if present)
2) The defined formulation or dosage form (capsule/tablet, controlled release, unit dose, etc., if the independent claims specify them)
3) The treatment indication and dosing regimen (if independent or dependent claims recite the therapeutic use and dosing schedule)
| Claim scope structure (functional mapping) |
Claim bucket |
Typical independent scope in AU pharma files |
What usually limits infringement |
| Composition |
Drug plus defined pharmaceutical form/excipients |
Different salt/polymorph, different dosage form, absence of required composition parameters |
| Method of treatment |
Patient treatment for a therapeutic indication using the composition |
Different indication, different regimen, non-claimed dosing windows |
| Dependent refinements |
Substituted variations, dosage ranges, population subsets |
“Missing” required limitations in a downstream product or label |
What does the claims set likely require for infringement risk?
For a downstream competitor in Australia, infringement risk generally tracks whether the product falls inside all limitations of at least one independent claim, or inside a dependent claim’s narrower limitation set if the independent is broad.
Infringement risk drivers
- Active ingredient definition: any deviation in salt form or polymorph language (if claimed) can reduce scope.
- Dosage form: controlled release vs immediate release, unit dose structure, and excipient-defined constraints are common narrowing points.
- Indication and regimen: Australian method claims often require a specific therapeutic use and dosing logic; products that target a different indication or dose may avoid literal coverage.
How broad is the scope compared with common Australian pharma claim patterns?
AU2016206297 sits in the standard Australian pharmaceutical claims framework where:
- Independent claims are drafted to capture a central invention point (composition and/or method).
- Dependent claims pull the boundary tighter around particular formulations or dosing regimens.
- Enforcement leverage typically concentrates on composition-related claims when formulation specifics are met, and on method claims when prescribing instructions and labeling match.
In practice, claim breadth is usually medium-to-high for the core composition concept and lower for heavily specified dependent variants, which matters for both clearance and freedom-to-operate (FTO) planning.
What is the patent landscape around AU2016206297 in Australia?
Which other patent families typically intersect this space?
Australian pharma families that map to a given drug concept often intersect through multiple related layers:
1) Primary compound and/or composition families (often filed earliest, with medium term coverage)
2) Formulation and delivery system families (controlled release, dosing device, excipient matrix, stability)
3) New indication or dosing regimen families (later priority dates, narrower method claims)
4) Polymorph/salt and process families (coverage can be composition-focused or process-limited)
AU2016206297’s place in the landscape depends on its filing priority relative to earlier compound patents and later formulation or indication follow-ons.
How do claim overlap and estate timing usually play out?
In Australia, the effective competitive landscape around a given drug is driven by:
- Priority date ordering across families (earlier filings create the baseline).
- Expiry and term adjustments (standard 20-year patent term from the earliest priority date in most cases).
- Branching follow-on filings that extend commercial coverage via formulation or indication.
Downstream risk rises sharply when:
- AU2016206297’s independent claims align with a competitor’s intended product concept, and
- related families are still active in parallel (so that avoiding one claim set can still leave exposure under another).
What is the regulatory and enforcement relevance in Australia?
How does patent scope interact with Australian market entry planning?
For market entry strategies in Australia, AU2016206297’s claim boundaries typically feed into:
- Label and prescribing instructions alignment: method claim exposure depends on the indication and dosage regimen actually used.
- Product design choices: formulation and dosage form choices can be decisive where composition claims require specific structural parameters.
- Design-around feasibility: controlled-release features, excipient selection, and salt/polymorph selection are common levers.
Practical claim and landscape takeaways for AU2016206297
Where is the enforceable scope most likely concentrated?
| Patent element |
Most likely enforceable leverage |
Typical competitors’ design-around path |
| Composition language in independent claims |
Direct infringement risk if product matches composition and dosage form |
Swap dosage form, alter salt/polymorph, modify excipient-defined parameters |
| Treatment method language |
Risk depends on therapeutic use and dosing regimen used in practice |
Target different indication, modify regimen, avoid label-driven matching |
| Dependent claim refinements |
Lower breadth but strong fallback if core composition is close |
Alter narrow parameters to fall outside dependent limitations |
What does this mean for freedom-to-operate screening in Australia?
A clearance search keyed to AU2016206297 should treat the patent as:
- A claim set with both composition and method angles (typical for pharma), and
- A potential blocking or overlapping family if other still-in-force patents in the same drug ecosystem cover the compound, delivery system, or indications.
Key Takeaways
- AU2016206297’s scope is defined by independent claims that lock onto an active ingredient concept and then narrow via formulation and treatment-specific dependent claims.
- Infringement risk in Australia tracks product fit to every limitation in at least one independent claim and, failing that, the limiting features in dependent claims.
- The most consequential landscape overlap usually comes from adjacent families on the same drug: formulation/delivery, indication/dosing, and salt/polymorph.
- For market entry planning, the highest-leverage design variables are dosage form, salt/polymorph, excipient-defined composition parameters, and indication/regimen alignment for method claims.
FAQs
1) What claim types usually exist in AU drug patents like AU2016206297?
They usually include composition claims (drug plus defined formulation parameters) and method-of-treatment claims (treating a therapeutic indication using the composition), with dependent claims narrowing by dosage regimen, formulations, or patient/indication specifics.
2) How do downstream products avoid AU2016206297 exposure?
The typical pathways are to design around the exact limitation set: change dosage form and formulation parameters, use a different salt/polymorph if that is claimed, and ensure therapeutic use and dosing do not track the method claim limitations.
3) Why do method-of-treatment claims matter for label strategy in Australia?
Method claims can be triggered by how the drug is actually used in practice. Label, indication, and dosing instructions can determine whether prescribing aligns with the claimed therapeutic use and regimen.
4) How does the broader patent landscape affect risk beyond AU2016206297?
Even if a product avoids AU2016206297 limitations, other still-in-force families in the same drug ecosystem (compound, formulation, delivery, dosing, or new indications) can create parallel exposure.
5) What is the fastest way to identify practical blocking coverage?
Map the independent claims to the competitor’s product concept: active ingredient definition, dosage form/formulation parameters, and the targeted indication and dosing regimen used in practice.
References
[1] Australian Patent Office (IP Australia). Patent search entry for AU2016206297.
[2] Australian Government. Patent term and general principles of Australian patent enforcement (Pharmaceutical patent context).
